Dr. Laura L. Tenner
Claim this profileNebraska Medicine-Bellevue
Studies Breast Cancer
Studies Colon Cancer
7 reported clinical trials
17 drugs studied
Area of expertise
1Breast Cancer
Stage IV
Stage III
DPD negative
2Colon Cancer
Stage IV
dMMR positive
MSI-H positive
Affiliated Hospitals
Clinical Trials Laura L. Tenner is currently running
Nivolumab + Standard Treatment
for Stomach and Esophageal Cancer
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Adding nivolumab to ramucirumab and paclitaxel may work better to treat patients with advanced stomach or esophageal cancer.
Recruiting1 award Phase 2 & 320 criteria
Ablative Therapy + Systemic Therapy
for Colorectal Cancer
This phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer that has spread to up to 4 body sites (limited metastatic). The usual approach for patients who are not participating in a study is treatment with intravenous (IV) (through a vein) and/or oral medications (systemic therapy) to help stop the cancer sites from getting larger and the spread of the cancer to additional body sites. Ablative means that the intention of the local treatment is to eliminate the cancer at that metastatic site. The ablative local therapy will consist of very focused, intensive radiotherapy called stereotactic ablative radiotherapy (SABR) with or without surgical resection and/or microwave ablation, which is a procedure where a needle is temporarily inserted in the tumor and heat is used to destroy the cancer cells. SABR, surgical resection, and microwave ablation have been tested for safety, but it is not scientifically proven that the addition of these treatments are beneficial for your stage of cancer. The addition of ablative local therapy to all known metastatic sites to the usual approach of systemic therapy could shrink or remove the tumor(s) or prevent the tumor(s) from returning.
Recruiting2 awards Phase 3
More about Laura L. Tenner
Clinical Trial Related1 year of experience running clinical trials · Led 7 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Laura L. Tenner has experience with
- Capecitabine
- Carboplatin
- Cisplatin
- Temozolomide
- Nivolumab
- CAPEOX
Breakdown of trials Laura L. Tenner has run
Breast Cancer
Colon Cancer
Colorectal Cancer
Neuroendocrine Carcinoma of the Skin
Pancreatic Neuroendocrine Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Laura L. Tenner specialize in?
Is Laura L. Tenner currently recruiting for clinical trials?
Are there any treatments that Laura L. Tenner has studied deeply?
What is the best way to schedule an appointment with Laura L. Tenner?
What is the office address of Laura L. Tenner?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.